Personalized Medicine in Ovarian Cancer: A Perspective From Mexico
Fernández Garza, Luis E. y Domínguez Vigil, Irma G. y Garza Martínez, José y Valdez Aparicio, Erick A. y Barrera Barrera, Silvia A. y Barrera Saldaña, Hugo A. (2021) Personalized Medicine in Ovarian Cancer: A Perspective From Mexico. World Journal of Oncology, 12 (4). pp. 85-92. ISSN 1920-4531
Texto
27187.pdf.crdownload - Versión Publicada Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) |
Resumen
Ovarian cancer (OC) represents a serious health problem worldwide. In Mexico, most OC patients are detected at late stages, consequently making OC one of the leading causes of death in women after reaching puberty. Personalized medicine (PM) provides an individualized therapeutic opportunity for treating each patient relying on “omic” tools to match the correct drug with the specific pathogenic genomic signature. PM can help predict the best therapeutic option for each affected woman suffering from OC. In recent years, Mexico has made contributions to the PM of OC; however, it still has a long way to go for its full implementation in the country’s health system.
Tipo de elemento: | Article | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Palabras claves no controlados: | Medicina personalizada; Cáncer de ovarios; Terapias dirigidas; México | |||||||||||||||||||||
Materias: | R Medicina > RG Ginecología y Obstetricia | |||||||||||||||||||||
Divisiones: | Medicina | |||||||||||||||||||||
Usuario depositante: | Dr Irma G Dominguez Vigil | |||||||||||||||||||||
Creadores: |
|
|||||||||||||||||||||
Fecha del depósito: | 21 Mar 2024 16:03 | |||||||||||||||||||||
Última modificación: | 21 Mar 2024 16:12 | |||||||||||||||||||||
URI: | http://eprints.uanl.mx/id/eprint/27187 |
Actions (login required)
Ver elemento |